A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...
The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion ...
The Inflation Reduction Act (IRA) has modestly boosted oncology biosimilar uptake through Medicare reimbursement, but its ...
The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory ...
Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics ...
Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by ...
Number 1: Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American patients with retinal diseases. To read all of these articles and more, ...
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback